News | Contrast Media Injectors | June 29, 2020

Guerbet Segments Consumables in Two Essential and Excellence Ranges

Guerbet shows its commitment to healthcare professionals with two ranges of consumables selected for their injection solutions

Guerbet shows its commitment to healthcare professionals with two ranges of consumables selected for their injection solutions

June 29, 2020 — Guerbet has launched a new "consumables.guerbet.com" website presenting its Essential and Excellence ranges of consumables for use with injection solutions and tailored for diagnostic imaging professionals.

Essential certified by Guerbet is a range of easy-to-use consumables certified by Guerbet and supplied by manufacturers selected by the company. They are all tested and approved according to Guerbet quality standards and comply with medical devices regulations. 

Excellence designed by Guerbet is a range of consumables designed from Guerbet research offering innovative1 safety features and improving the workflow of injection procedures.

"We have segmented our consumables in two clearly identified Essential and Excellence ranges to make it easier for healthcare professionals to reach decisions. All our consumables are compatible with our CT, Cath Lab and MRI injection systems and benefit from our commitment to delivering safe, high-quality solutions crucial for improving patient prognosis and quality of life," said Valérie Brissart, Global Marketing Director of CT and Cath Lab Imaging Solutions at Guerbet.

Both ranges of consumables offer syringes and kits, patient lines, day-sets, tubing and accessories for each of the Guerbet power injectors: OptiVantage Multi-use, OptiVantage Single-use, Illumena Néo, FlowSens, OptiStar Elite, OptiOne.

For more information: consumables.guerbet.com

 

1Vermeulen C, Noury B & Al. - Microbial Safety Assessment of a Double Check-Valve Patient Line in a Multi-use Contrast Delivery System Radiol Technol. 2015 Nov-Dec;87(2):139-49

Related Content

the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite
News | Contrast Media | August 14, 2020
August 14, 2020 — The U.S.
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma. The quarter dose image on the left was obtained after the administration of 4 ml of MultiHance. Subsequently, an additional 12 ml of MultiHance was administered and the cumulative full dose image in the center was obtained. The image on the right was rendered following artificial intelligence processing of the 4 ml image using eGad genetic algorithms. This image has the quality of triple dose gadolinium even though only one quarter dose gadolinium was given.

Feature | Contrast Media Injectors | January 30, 2020 | By Matthew Kuhn, M.D., FACR
Gadolinium-based contrast agents (...